SEARCH

SEARCH BY CITATION

References

  • 1
    Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97107.
  • 2
    Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 6573.
  • 3
    Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 15211531.
  • 4
    Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 10111020.
  • 5
    Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 10011010.
  • 6
    Heathcote EJ, Gane E, de Man RA, Chan S, Sievert W, Mauss S, et al. Two year tenofovir disoproxil fumarate treatment and adefovir dipivoxil switch data in HBe-Ag-positive patients with chronic hepatitis B (study 103), preliminary analysis. HEPATOLOGY 2008; 48 ( Suppl. 4): 376.
  • 7
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227242.
  • 8
    Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6: 13151341; 1286.
  • 9
    Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12: 17351744.
  • 10
    Patel V, Hedayati SS. Lactic acidosis in an HIV-infected patient receiving highly active antiretroviral therapy. Nat Clin Pract Nephrol 2006; 2: 109114; 115.
  • 11
    Schiff E, Simsek H, Lee WM, Chao YC, Sette H Jr, Janssen HL, et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008; 103: 27762783.
  • 12
    Nelson M, Azwa A, Sokwala A, Harania RS, Stebbing J. Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy. AIDS 2008; 22: 13741376.
  • 13
    Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. HEPATOLOGY 2009; 49 ( Suppl. 5): 185195.
  • 14
    Seok JI, Lee DK, Lee CH, Park MS, Kim SY, Kim HS, et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. HEPATOLOGY 2009; 49: 20802086.
  • 15
    Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 25762588.
  • 16
    Adani GL, Baccarani U, Risaliti A, Bresadola F, Della Rocca G, Viale P. Rhabdomyolysis due to Lamivudine administration in a liver transplant recipient. Am J Transplant 2005; 5: 634.
  • 17
    Bayrakci US, Baskin E, Ozcay F, Ozdemir BH, Karakayali H, Haberal M. Renal Fanconi syndrome and myopathy after liver transplantation: drug-related mitochondrial cytopathy? Pediatr Transplant 2008; 12: 109112.
  • 18
    Cohen SM, Levy RM, Jovanovich JF, Ahn J. Fatal lactic acidosis associated with the use of combination oral medications to treat reactivation of hepatitis B. J Clin Gastroenterol 2009; 43: 10081010.
  • 19
    Mazzucco CE, Hamatake RK, Colonno RJ, Tenney DJ. Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition. Antimicrob Agents Chemother 2008; 52: 598605.
  • 20
    Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997; 41: 14441448.